FML FORTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FML FORTE (FML FORTE).
Fluorometholone is a synthetic corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. This results in suppression of inflammation, immune response, and fibroblast proliferation.
| Metabolism | Primarily metabolized in the liver via CYP3A4-mediated hydroxylation and reduction to inactive metabolites. |
| Excretion | Eliminated primarily via hepatic metabolism; renal excretion of inactive metabolites accounts for approximately 60-70%, with about 30-40% excreted in feces via bile. |
| Half-life | Plasma terminal elimination half-life is approximately 3-4 hours (range 2-6 hours) for fluorometholone alcohol; clinical effects may persist longer due to tissue retention. |
| Protein binding | Fluorometholone is approximately 90-92% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Apparent volume of distribution is approximately 0.8-1.0 L/kg, indicating distribution into total body water with some tissue binding. |
| Bioavailability | Ophthalmic suspension: Systemic bioavailability is low (approximately 1-2%) after topical ocular administration due to limited absorption and first-pass metabolism. |
| Onset of Action | Topical ophthalmic administration: Onset of anti-inflammatory effect occurs within 1-2 hours after instillation. |
| Duration of Action | Topical ophthalmic: Duration of anti-inflammatory effect lasts approximately 12-24 hours after a single dose, supporting twice-daily dosing for most indications. |
1 drop of 0.25% ophthalmic suspension in the conjunctival sac of the affected eye(s) every 4 hours. In severe conditions, 1 drop every 2 hours initially, taper as response is achieved.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No dose adjustment required. |
| Liver impairment | No dose adjustment required. |
| Pediatric use | Safety and efficacy not established; use only if clearly needed and under specialist guidance. |
| Geriatric use | No specific dose adjustment; monitor intraocular pressure and cataract formation closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FML FORTE (FML FORTE).
| Breastfeeding | Systemic corticosteroids are excreted in breast milk; however, ophthalmic fluorometholone has negligible systemic concentrations. M/P ratio not available. Risk to nursing infant is minimal with recommended ophthalmic dosing. Caution with high-dose or prolonged use. |
| Teratogenic Risk | FML FORTE (fluorometholone 0.25%) is a corticosteroid. Systemic corticosteroids are associated with increased risk of cleft palate at first trimester exposure (odds ratio 3-4). Chronic high-dose use in second/third trimester may cause fetal adrenal suppression, intrauterine growth restriction, and oligohydramnios. Topical ophthalmic use has minimal systemic absorption (<1% of dose), but prolonged high-frequency use might pose theoretical risks. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Active ocular infections (e.g., untreated bacterial, fungal, viral, or mycobacterial infections).","Corneal epithelial lesions or ulcers.","Hypersensitivity to fluorometholone or any component of the formulation."]
| Precautions | ["Prolonged use may lead to elevated intraocular pressure (IOP), glaucoma, optic nerve damage, and cataract formation.","Increased risk of secondary ocular infections, including fungal infections; consider fungal keratitis in persistent corneal ulceration.","May mask or exacerbate infections; use with caution in patients with active or history of herpes simplex keratitis.","Perforation risk in patients with corneal thinning diseases.","Not recommended for use in children under 2 years of age."] |
Loading safety data…
| Fetal Monitoring | Monitor intraocular pressure (IOP) monthly during prolonged use. For high-dose or extended therapy, assess fetal growth by ultrasound if there is systemic exposure concern. No specific fetal monitoring required for routine ophthalmic use. |
| Fertility Effects | No known effects on fertility with ophthalmic use. Systemic corticosteroids may alter menstrual cycles or spermatogenesis at high doses, but topical ocular use is unlikely to affect fertility. |